

1 **D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization**

2
3 Drew Weissman^{1*}, Mohamad-Gabriel Alameh¹, Celia C. LaBranche², Robert J
4 Edwards^{3, 4}, Laura Sutherland³, Sampa Santra⁵, Katayoun Mansouri³, Sophie Gobeil³,
5 Charlene McDanal², Norbert Pardi¹, Pamela A. Shaw⁶, Mark G. Lewis⁷, Carsten
6 Boesler⁸, Uğur Şahin⁸, Priyamvada Acharya³, Barton F. Haynes³, Bette Korber⁹, David
7 C. Montefiori^{2*}

8
9 ¹Division of Infectious Diseases, University of Pennsylvania Perelman School of
10 Medicine, Philadelphia, PA USA, ²Duke Human Vaccine Institute & Department of
11 Surgery, Durham, North Carolina USA, ³Duke Human Vaccine Institute, Duke University
12 School of Medicine, Durham, NC USA, ⁴Duke University, Department of Medicine,
13 Durham NC USA, ⁵Center for Virology and Vaccine Research, Beth Israel Deaconess
14 Medical Center, Harvard Medical School, Boston, Massachusetts USA, ⁶Department of
15 Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School
16 of Medicine, Philadelphia, PA USA, ⁷Bioqual Inc., Rockville, MD USA, ⁸BioNTech,
17 Mainz, Germany ⁹T6: Theoretical Biology and Biophysics, Los Alamos National
18 Laboratory, Los Alamos, NM USA.

19
20 * Address correspondence to Drew Weissman, drew@penmedicine.upenn.edu or
21 David Montefiori, david.montefiori@duke.edu.

26 Abstract

27

28 The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-
29 19 pandemic that appears to confer on the virus greater infectivity and now globally is
30 the dominant form of the virus. Certain of the current vaccines entering phase 3 trials
31 are based on the early D614 form of Spike with the goal of eliciting protective
32 neutralizing antibodies. To determine whether D614G mediates neutralization-escape
33 that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman
34 primates and humans were evaluated for neutralization of pseudoviruses bearing either
35 D614 or G614 Spike on their surface. In all cases, G614 Spike pseudovirions were
36 moderately more susceptible to neutralization, indicating this is not an escape mutation
37 that would impede current vaccines. Rather, the gain in infectivity provided by D614G
38 came at the cost of making the virus more vulnerable to neutralizing antibodies.

39

40

41

42
43 There is an urgent worldwide need to develop a safe and effective vaccine to
44 help end the COVID-19 pandemic. SARS-CoV-2, the etiologic agent of COVID-19, is a
45 novel coronavirus that was first reported in Wuhan, China in December, 2019 and four
46 months later was declared a pandemic by the World Health Organization. Vaccine
47 efforts began shortly after the first sequence of the virus was made available in January
48 2020¹. Presently, at least 23 SARS-CoV-2 vaccines are in clinical trials
49 ([https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
50 [vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)). Because of the urgency and time required to develop a vaccine, most
51 COVID-19 vaccines entering phase 3 trials are based on an early index strain of the
52 virus. These vaccines focus on the viral Spike protein with the goal of eliciting protective
53 neutralizing antibodies.

54
55 The trimeric Spike protein mediates virus attachment and entry into host cells².
56 Each monomer is comprised of an S1 subunit, which contains the receptor binding
57 domain (RBD), and an S2 subunit that mediates membrane fusion³. The RBD is the
58 primary target of neutralizing antibodies, though the N-terminal domain and other
59 regions of Spike are also known to possess neutralization epitopes^{2,4-11}


60
61 Early in the pandemic, the virus acquired a mutation, D614G, in the Spike protein
62 that rapidly increased in frequency and is now the dominant form of the virus globally¹².
63 The pattern of spread, combined with increased infectivity *in vitro*, suggests the
64 mutation gave the virus a fitness advantage for transmission^{12,13}. The mutation is also
65 associated with higher virus loads in respiratory secretions but does not appear to
66 increase virulence¹². A critical question is whether this mutation also mediates
67 neutralization-escape that may reduce the effectiveness of vaccines in general and
68 especially ones based on the D614 version of the Spike immunogen.

69
70 Here, we addressed this question using sera from Spike-immunized mice,
71 nonhuman primates and humans. Neutralization was measured in 293T/ACE2 cells
72 using lentivirus particles pseudotyped with full-length SARS-CoV-2 Spike containing
73 either D614 or G614. As this was the only difference between the pseudoviruses, any
74 change in phenotype can be directly attributed to D614G. Assays were performed with
75 nearly equivalent amounts of input virus doses (relative light unit (RLU) in virus control
76 wells were 501-840x background in all assays).

77
78 Mice, rhesus macaques, and humans were immunized with the nucleoside-
79 modified mRNA-LNP vaccine platform^{14,15} and one of four different forms of the Spike
80 immunogen, including monomeric and trimeric secreted RBD and diProline
81 stabilized^{3,16,17} or Wuhan index strain¹ with a mutated furin cleavage site cell associated
82 trimeric Spike. The furin mutant potentially stabilizes the full-length Spike and maintains
83 the association of the S1 and S2 subunits¹⁶. Pseudoviral neutralization titers were
84 calculated as 50% and 80% inhibitory doses (ID₅₀ and ID₈₀, respectively).

85
86 A total of forty mice were immunized twice at a 4-week interval with nucleoside-
87 modified mRNA encoding the diProline stabilized cell surface D614 Spike^{3,16,17} in four

88 equal sized groups, with varying dose and route of vaccine administration. This is the
89 immunogen being employed in the Moderna vaccine entering phase 3 clinical trials
90 (mRNA-1273)¹⁸. Immunizations were performed by the intradermal (ID) and
91 intramuscular (IM) routes with 10 and 30 µg doses. Preimmune and serum 4 weeks
92 after the second immunization were analyzed for neutralization of pseudoviruses with
93 the D614 and G614 sequences. Preimmune sera from all mice scored negative. At 4
94 weeks after the second immunization, a relative increase in NAb titer for G614 over
95 D614 was observed for each animal (Figures 1a and S1a, Table S1); analyses were
96 done both as a single group and separately by dose and route. Across all routes and
97 doses (N=40), the geometric mean for the G614:D614 ratio was 5.16-fold ($p < 0.001$) for
98 ID₅₀ and for 4.44 for ID₈₀ ($p < 0.001$). Similar patterns were seen across the 10 µg and 30
99 µg doses and for both IM and ID routes (Table 1). Table 1 shows the geometric mean
100 for the ratio of G614:D614 NAb titers across route and doses, which ranged from, 3.87
101 to 6.49 ID₅₀ and 4.29-4.57 ID₈₀ with $p < 0.001$ for all comparisons.
102



103
104 Figure 1. The G614 Spike is neutralized at a higher level than the D614 Spike by sera from
105 mice, rhesus macaques, and humans immunized with nucleoside-modified mRNA-LNPs
106 encoding RBD and full-length Spike immunogens. (a) Sera from mice (10 animals/group)
107 immunized twice at a 4-week interval with nucleoside-modified mRNA-LNPs encoding the
108 Wuhan sequence of Spike (D614) with diProline stabilization mutations obtained 4 weeks after
109 the second immunization were tested for neutralization against pseudoviruses with the D614

110 and G614 variants of Spike. Sera from macaques immunized twice at a 4-week interval with
111 nucleoside-modified mRNA-LNPs encoding the Wuhan sequence of Spike (D614) with a
112 mutated furin cleavage site (n= 5) **(b)** or secreted RBD monomers (n= 6) **(c)** obtained 4 weeks
113 after the second immunization were tested for neutralization against pseudoviruses with the
114 D614 and G614 variants of Spike. **(d)** sera from 5 humans immunized twice at a 3-week interval
115 with nucleoside-modified mRNA-LNPs encoding a secreted RBD trimer. Each dot represents
116 one mouse, macaque, or human. The line connects analyses from individual animals or
117 humans.
118

Dose	Intramuscular		Intradermal	
	ID ₅₀	ID ₈₀	ID ₅₀	ID ₈₀
10 µg	6.49 (p<0.001)	4.50 (p<0.001)	5.60 (p<0.001)	4.41 (p<0.001)
30 µg	5.16 (p<0.001)	4.57 (p<0.001)	3.87 (p<0.001)	4.29 (p<0.001)

119
120 Table 1: Geometric mean (ratio t-test p-value) for the ratio of G614:D614 neutralizing antibodies
121 measured in murine sera 4 weeks post second immunization with 10 or 30 µg of diProline
122 stabilized Wuhan sequence Spike encoding mRNA-LNPs, administered via either IM or ID
123 route, with 10 mice per group.
124

125 Eleven rhesus macaques were immunized with the nucleoside-modified mRNA-
126 LNP vaccine platform using 2 different immunogens by the IM route (50 µg). The first
127 encoded the Wuhan index strain sequence¹ cell surface Spike protein with a mutated
128 furin cleavage site (furin mut). The second encoded the RBD domain as a secreted
129 monomer. Sera obtained at baseline and 4 weeks after the second immunization were
130 assessed for neutralization of the D614 and G614 variants (Figure 1b and c, Figure S1b
131 and c, Table S1). Baseline (pre-immune) sera were all negative. Post-immunization
132 sera exhibiting greater neutralization of the G614 variant virus for both immunogens. For
133 the cell surface Spike immunogen with a mutated furin site (N=5), the geometric mean
134 for the G614: D614 ID₅₀ NAb titer ratio was 5.37-fold (p = 0.001) and for ID₈₀ was 2.89-
135 fold (p < 0.001) (Figure 1b). For the soluble RBD (N=6), the G614:D614 ID₅₀ NAb titer
136 ratio had a geometric mean of 6.45-fold (p < 0.001) and for ID₈₀ was 3.22-fold (p<
137 0.001) (Figure 1c). The observation that the G variant was more sensitive to antibodies
138 induced by both a D614 containing cell surface Spike trimer and an RBD secreted
139 monomer suggests that the G614 mutation increases RBD mediated neutralization.
140


141 Preliminary results from a phase 1/2 clinical trial using the nucleoside-modified
142 mRNA-LNP vaccine platform that delivered a secreted RBD trimer was recently
143 published and demonstrated potent ELISA binding and neutralization in all subjects at
144 all tested doses, 10, 30, and 100 µg¹⁹. Virus neutralizing titers after the second
145 immunization of 10 and 30 µg were 1.8-fold and 2.8-fold greater, respectively, than a
146 convalescent serum panel from SARS-CoV-2 infected patients¹⁹, although the
147 convalescent patients had a wide range and were older than vaccinated subjects.
148

149 Sera obtained preimmunization and 7 days after the second immunization with
150 50 µg (N=3), 30 µg (N=1), and 10 µg (N=1) of human subjects from a phase 1 trial
151 performed in Germany using the same vaccine were analyzed for neutralization of the
152 D614 and G614 Spike variant pseudoviruses. Similar to the data in murine and NHP

153 immunizations, the G614 pseudovirus was more potently neutralized compared to the
154 D614 pseudovirus by the same serum samples (Figures 1d and S1d, Table S1). The
155 geometric mean of the G614:D614 ID₅₀ NAb titer ratio was 4.22-fold ($p = 0.014$) and for
156 ID₈₀ was 3.1-fold ($p = 0.017$). No neutralizing activity was detected in the corresponding
157 preimmune sera.

158
159 The observation that sera from macaques and humans immunized with RBD-
160 only immunogens also enhanced neutralization of the G614 pseudovirus suggested that
161 the elicited response was RBD-directed, and the neutralization enhancement was due
162 to a structural change in the expressed Spike. To evaluate this possibility, we used
163 negative stain electron microscopy (EM) and single particle reconstruction coupled with
164 3D classification to determine the structure and variability of the two variants in furin-
165 deficient Spike ectodomain (Figure S2) constructs. The D614 variant showed two
166 classes (Figure 2A), called “3-down” or “1-up” in reference to their RBD positions. The
167 D614 variant showed a roughly equal proportion of the 3-down to 1-up states (54%
168 versus 46%) (see methods), consistent with the findings observed by cryo-EM²⁰. The
169 G614 variant also showed 3-down and 1-up structures (Figure 2B); however, the 1-up
170 state was more heavily populated, 82%, in the G614 variant. This shift to the 1-up
171 state as the dominant form in the Spike ectodomain demonstrates an allosteric effect of the
172 D614G mutation on the RBD conformation, and suggests a mechanism for the
173 enhanced neutralization susceptibility of the G614 variant.

174
175



176
177
178 Figure 2. Negative stain electron microscopy reconstructions of expressed Spike constructs
179 following 3D classification. View is looking down the 4-fold trimer axis onto the S1 domain. (A)

180 D614 variant showing the 3-RBD-down structure on the left with individual RBDs labeled (R),
181 and the 1-RBD-up structure on the right with the up RBD labeled (asterisk). Fraction of particle
182 images that sorted into each class indicated below, expressed as average \pm standard deviation,
183 N=3 each. (B) G614 variant also showing 3-down and 1-up structures.

184

185 Soon after the G614 mutation in Spike appeared early in the pandemic it rapidly
186 replaced the D614 variant in many countries¹². This mutation is associated with
187 increased infectivity^{12,13} when tested in in vitro model systems. Over 100 vaccines using
188 various platforms and immunogens are being developed to combat COVID-19 and end
189 the devastating financial, societal, and health burdens. Currently, 23 vaccines are in
190 clinical testing, some of which will soon enter phase 3 trials. Most SARS-CoV-2
191 vaccines were originally designed using the D614 variant of the Spike protein, which
192 was present in the first sequence of SARS-CoV-2 from Wuhan¹. The most critical
193 finding that will ease the concern for most current vaccines in clinical trials is the finding
194 that the SARS-CoV-2 Spike protein with the G614 mutation is neutralized at a higher
195 level by serum from vaccinated mice, NHPs, and humans that used immunogens
196 derived from the D614 variant of the virus.

197

198 D614 is on the surface of the Spike protomer. It can potentially form contacts with
199 a neighboring trimer subunit. The recently published cryo-EM structure of the SARS-
200 CoV-2 Spike demonstrates that the D614 sidechain can form a hydrogen bond with the
201 neighboring protomer T859³. This interaction may be critical, as it may bridge residues
202 from the S1 region of one protomer to the S2 region of an adjacent protomer. This
203 interaction would bracket the furin and S2 cleavage sites. Potentially, it could reduce
204 shedding of S1 from viral-membrane-bound S2 and the introduction of G614 would
205 increase S1 release. Our structural data demonstrates that, in the context of the
206 stabilized ectodomain, this mutation leads to an increase in the percent of 1 RBD region
207 per trimer being in the up position, which is necessary for binding to ACE2 and infection
208 of target cells (Figure 2). A recent publication demonstrated a similar effect of the G614
209 mutation to increase the number of RBDs in the up position²¹. Using an alternative
210 structural analysis method, extensive microsecond timescale atomistic molecular
211 dynamics simulations, reveal that in the G-form, the inter-protomer interactions in the
212 Spike trimer become more symmetric compared to the D-form. This equalization of
213 inter-protomer energetics results in a higher population of one-up Spike conformations,
214 leading to increased encounter between RBD and ACE2 receptor and greater exposure
215 of RBD domain for neutralization (Gnana, personal communication to be replaced with
216 Biorxiv).

217

218 Potential drawbacks to our studies include: 1) while we studied 4 different
219 variations of the Spike immunogen, we only used a single type of vaccine, the
220 nucleoside-modified mRNA-LNP platform (reviewed in ^{15,22}). This platform is recognized
221 as an outstanding new approach that will enter phase 3 clinical trials by 2 separate
222 pharmaceutical/biotech companies, Moderna and Pfizer/BioNTech. The results of phase
223 1 clinical trials by Pfizer/BioNTech and Moderna demonstrated that all immunized
224 subjects safely developed neutralizing responses^{18,19}. 2) We performed pseudovirus
225 neutralization assays. While these assays are considered excellent methods to
226 measure neutralization and are used for the development of many viral vaccines, live

227 virus neutralization or animal challenges would offer additional methods to measure
228 vaccine response to the G614 variant. As with the pseudovirus assay, assays with live
229 SARS-CoV-2 are performed with viruses that are produced and assayed in cell lines;
230 neutralization assays that use natural target cells of the respiratory system are
231 technically challenging, low throughput and difficult to standardize. 3) Our structural
232 studies were performed in the context of a furin cleavage-deficient Spike ectodomain.
233 While this soluble ectodomain has been shown to be a good mimic of the native Spike,
234 and the shift in the proportion of RBD “up” conformation between the D614 and G614
235 forms suggest an allosteric effect of the D614G mutation on the RBD conformations, the
236 structures of the native Spike may have some differences from what we observe in the
237 context of the ectodomain.

238
239 We demonstrate that vaccinated mice, NHPs, and humans using the nucleoside-
240 modified mRNA-LNP vaccine platform encoding 4 different SARS-CoV-2 Spike
241 immunogens generate antibody responses that not only recognize the G614 mutation
242 that has taken over the pandemic in many countries and has demonstrated increased
243 infectivity^{13 12}, they have stronger titers of neutralization to this virus variant. The
244 mechanism appears to be that the mutation increases the up formation of the RBD in
245 the Spike trimer, increasing the exposure of neutralization epitopes. Twenty-three
246 vaccines are currently in clinical trial testing. Most of the immunogens used were either
247 derived from the initial D614 virus or contain this mutation in the Spike. The observation
248 that the G614 variant that has replaced the original D614 mutation in the SARS-CoV-2
249 Spike throughout much of the world is not an escape mutation and, in fact, is better
250 neutralized by sera from mice, NHPs, and humans immunized with immunogens
251 containing or derived from the D614 viral Spike alleviates a major concern in the
252 development of an effective SARS CoV-2 vaccine.
253

254 **Methods**

255

256 **Ethics statement**

257

258 All in vivo experiments described in this manuscript were randomized double-
259 blinded and approved by the University of Pennsylvania (UPenn) IACUC. All protocols,
260 experimentation and animal manipulation adhered to the Guide for the Care and Use of
261 Laboratory Animals by the Committee on Care of Laboratory Animal Resources
262 Commission on Life Sciences, National Research Council.

263

264 **mRNA production**

265

266 N¹-methylpseudouridine modified mRNA was produced as previously described
267 ²³ using T7 RNA polymerase (MegaScript, ThermoFisher Scientific, Waltham, MA,
268 USA) on Not-I/AlfII double digested and linearized plasmids encoding codon-optimized
269 di-proline modified pre-fusion SARS-CoV-2 Spike (Wuhan Hu-1 complete genome,
270 GenBank: MN908947.3), full length S-fm protein (RRAR furin cleavage site abolished),
271 and RBD. In vitro transcribed (IVT) mRNAs were co-transcriptionally capped using the
272 CleanCap system (TriLink Biotechnologies, San Diego, CA, USA), and purified using a
273 cellulose-based chromatography method ²⁴. All IVT mRNAs were analyzed on agarose
274 (1.4 % w/v, 1X TAE buffer) for integrity, and subjected to additional quality control to
275 rule out double stranded RNA (dsRNA) contamination and endotoxin contamination
276 prior to formulations into lipid nanoparticles (LNPs), as described ²⁵.

277

278 **Production of mRNA-LNP**

279

280 Lipid nanoparticles (LNPs) used in this study contain ionizable lipids proprietary
281 to Acuitas /DSPC/Cholesterol/PEG-Lipid ²⁶. Encoding mRNA was encapsulated in LNPs
282 using a self-assembly process in which an aqueous solution of mRNA at 4.0 pH was
283 rapidly mixed with a solution containing the aforementioned lipids premixed at mol/ mol
284 percent ratio of 50:10:38.5:1.5 and dissolved in ethanol. mRNA was encapsulated into
285 LNPs at a nucleic acid to total lipid ratio of ~0.05 (wt/wt) and aliquoted at a nucleic acid
286 concentration of ~1 mg/ml. All LNPs were characterized post-production at Acuitas
287 pharmaceutical (Vancouver, BC, Canada) for their size, surface charge using a Malvern
288 Zetasizer (Zetasizer Nano DS, Malvern, UK), encapsulation efficiency, and shipped on
289 dry ice and stored at -80°C until use.

290

291 **Administration of test articles (immunization) and blood collection**

292

293 8-12 week old Balb/c mice were immunized with either 10 µg of mRNA-LNPs via
294 the intramuscular (IM) route of administration using a 29G X1/2" Insulin syringe. Mice
295 received a booster injection on day 28 (4 weeks). Blood was collected at day 0, 28 and
296 56 through the retro-orbital route using non heparinized micro hematocrit capillary tubes
297 (ThermoFisher Scientific, Waltham, MA, USA). Serum was separated by centrifugation
298 (10 000 g, 5 min) using a non-refrigerated Eppendorf 5424 centrifuge (Eppendorf,

299 Enfield, CT, USA), heat-inactivated (56°C) for 30 minutes, and stored at -20° C until
300 analysis.

301

302 **Administration of mRNA/LNPs to rhesus macaques**

303

304 Fifty micrograms of either mRNA/LNPs encoding an unstabilized
305 transmembrane (TM) Spike protein or a monomeric soluble RBD were administered
306 intramuscularly in two sites in the left and right quadriceps on weeks 0, and 4.
307 Monkeys immunized 50 µg IM; 500 µL total (250 µL in R + L quad). Immunizations at
308 wk 0, 4. Animals were anesthetized with ketamine prior to blood draws from the femoral
309 vein. Serum samples were analyzed in 5 macaques immunized with mRNA/LNPs
310 encoding unstabilized TM Spike and in 6 animals immunized with mRNA/LNPs
311 encoding soluble RBD. All studies were performed at Bioqual, Inc, Rockville, MD
312 following IACUC approval.

313

314 **Clinical trial samples**

315

316 Serum from subjects enrolled in a phase 1/2 clinical trial of a nucleoside-modified
317 mRNA-LNP vaccine encoding trimeric SARS-CoV-2 RBDs (BNT162b1) were obtained
318 (NCT04380701). Five subjects that received 2 immunizations at a 3-week interval with
319 10, 30, or 50 µg of mRNA were used. All subjects were considered a single group, as
320 similar serologic data was obtained for each dose and the comparison and calculation
321 of statistical significance was performed within each sample. Serum was obtained prior
322 to the first immunization and 7 days after the second immunization.

323

324 **SARS-CoV-2 pseudovirus neutralization assay.**

325

326 SARS-CoV-2 neutralization was assessed with Spike-pseudotyped viruses in
327 293T/ACE2 cells as a function of reductions in luciferase (Luc) reporter activity.
328 293T/ACE2 cells were kindly provided by Drs. Mike Farzan and Huihui Mu at Scripps.
329 Cells were maintained in DMEM containing 10% FBS and 3 µg/ml puromycin. An
330 expression plasmid encoding codon-optimized full-length Spike of the Wuhan-1 strain
331 (VRC7480), was provided by Drs. Barney Graham and Kizzmekia Corbett at the
332 Vaccine Research Center, National Institutes of Health (USA). The D614G amino acid
333 change was introduced into VRC7480 by site-directed mutagenesis using the
334 QuikChange Lightning Site-Directed Mutagenesis Kit from Agilent Technologies
335 (Catalog # 210518). The mutation was confirmed by full-length Spike gene sequencing.
336 Pseudovirions were produced in HEK 293T/17 cells (ATCC cat. no. CRL-11268) by
337 transfection using Fugene 6 (Promega Cat#E2692) and a combination of Spike plasmid,
338 lentiviral backbone plasmid (pCMV ΔR8.2) and firefly Luc reporter gene plasmid (pHR'
339 CMV Luc)²⁷ in a 1:17:17 ratio. Transfections were allowed to proceed for 16-20 hours at
340 37°C. Medium was removed, monolayers rinsed with growth medium, and 15 ml of fresh
341 growth medium added. Pseudovirus-containing culture medium was collected after an
342 additional 2 days of incubation and was clarified of cells by low-speed centrifugation and
343 0.45 µm micron filtration and stored in aliquots at -80°C. TCID₅₀ assays were performed

344 on thawed aliquots to determine the infectious dose for neutralization assays (RLU 500-
345 1000x background, background usually averages 50-100 RLU).

346
347 For neutralization, a pre-titrated dose of virus was incubated with 8 serial 3-fold
348 or 5-fold dilutions of serum samples in duplicate in a total volume of 150 μ l for 1 hr at
349 37°C in 96-well flat-bottom poly-L-lysine-coated culture plates (Corning Biocoat). Cells
350 were suspended in TrypLE express enzyme solution (Thermo Fisher Scientific) and
351 immediately added to all wells (10,000 cells in 100 μ L of growth medium per well). One
352 set of 8 control wells received cells + virus (virus control) and another set of 8 wells
353 received cells (background control). After 66-72 hrs of incubation, medium was removed
354 by gentle aspiration and 30 μ L of Promega 1X lysis buffer was added to all wells. After a
355 10 minute incubation at room temperature, 100 μ L of Bright-Glo luciferase reagent was
356 added to all wells. After 1-2 minutes, 110 μ L of the cell lysate was transferred to a
357 black/white plate (Perkin-Elmer). Luminescence was measured using a PerkinElmer
358 Life Sciences, Model Victor2 luminometer. Neutralization titers are the serum dilution at
359 which relative luminescence units (RLU) were reduced by 50% and 80% compared to
360 virus control wells after subtraction of background RLUs. Serum samples were heat-
361 inactivated for 30 minutes at 56°C prior to assay.

362

363 **Protein expression and purification**

364

365 SARS-CoV-2 ectodomain constructs³ were produced and purified as follows.
366 Genes encoding residues 1–1208 of the SARS-CoV-2 S (GenBank: MN908947) with a
367 “GSAS” substitution at the furin cleavage site (residues 682–685), with and without
368 proline substitutions of residue K986 and V987 (S-GSAS/PP or S-GSAS), a C-terminal
369 T4 fibrin trimerization motif, an HRV3C protease cleavage site, a TwinStrepTag and an
370 8XHisTag were synthesized and cloned into the mammalian expression vector pαH.
371 The S-GSAS template was used to include the D614G mutation (S-GSAS(D614G)).
372 Plasmids were transiently transfected into FreeStyle-293F cells using Turbo293
373 (SpeedBiosystems). Protein was purified on the sixth day post-transfection from filtered
374 supernatant using StrepTactin resin (IBA), followed by size-exclusion chromatography
375 (SEC) purification using a Superose 6 10/300 GL column (GE healthcare) with
376 equilibrated in 2mM Tris, pH 8.0, 200 mM NaCl, 0.02% sodium azide buffer.

377

378 **Negative-stain electron microscopy**

379

380 Samples of S-GSAS and S-GSAS (D614G) ectodomain constructs were diluted
381 to 100 μ g/ml with room-temperature buffer containing 20 mM HEPES pH 7.4, 150 mM
382 NaCl, 5% glycerol and 7.5 mM glutaraldehyde, and incubated 5 min; then
383 glutaraldehyde was quenched for 5 min by addition of 1M Tris stock to a final
384 concentration of 75 mM. A 5- μ l drop of sample was applied to a glow-discharged,
385 carbon-coated grid for 10-15 s, blotted, stained with 2% uranyl formate, blotted and air-
386 dried. Images were obtained with a Philips EM420 electron microscope at 120 kV,
387 82,000 \times magnification, and a 4.02 Å pixel size. The RELION program²⁸ was used for
388 particle picking, 3D classification, and 3D refinements. The number of particle images

389 that sorted into each class during the classification provides an estimate of the fraction
390 for each state.

391

392 **Statistical methods**

393

394 For a given experiment, neutralizing antibody titers for G614 and D614 were
395 measured from serum on each animal and compared using a paired t-test of the
396 logarithm of the antibody titers (ratio t-test). This formally tests whether the ratio of the
397 titer is different from 1. All statistical tests were performed at the 0.05 level in the R
398 software (v3.6.1)²⁹.

399


400

401 **Supplementary tables**

402


403 **Table S1.** ID50, ID80 and maximum percent inhibition (MPI) values for all serum
404 samples assayed from mice, nonhuman primates and a phase 1/2 clinical trial.

405 **Supplementary figures**
406



407
408
409 **Figure S1.** The G614 Spike is more vulnerable to neutralization than D614 Spike by
410 vaccine-elicited serum antibodies. This figure accompanies Figure 1 and its legend. **(a,**
411 **b and c)** Percent neutralization values at each serum dilution for all animals in each
412 group were averaged. **(d)** Individual neutralization curves for the 5 vaccine recipients in
413 a phase 1/2 clinical trial of nucleoside-modified mRNA-LNPs encoding a secreted RBD
414 trimer. Orange, pseudovirus bearing D614 Spike; Blue, pseudovirus bearing G614
415 Spike.
416
417

418



419

420

421 **Figure S2. Purification the SARS-CoV-2 S ectodomain.** (A) Chromatogram of the
422 size-exclusion purification on a Supersose 6 GL 10/300 column of the Spike ectodomain
423 with proline mutations of residues 986 and 987 and furin cleavage site (residues 682–
424 685) mutated to GSAS (S-GSAS/PP; in black), of the S ectodomain with the proline
425 mutations reverted to the native K and V residues (S-GSAS; in red) and the Spike
426 ectodomain with the mutation D614G (S-GSAS(D614G); in green). (B) SDS-PAGE of
427 the purified protein (MW: molecular weight marker; 15 µg/lane).

428

429

430

431 References

- 432
- 433 1 Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 Vaccines at
434 Pandemic Speed. *N Engl J Med* **382**, 1969-1973 (2020), doi:10.1056/NEJMp2005630.
- 435 2 Yuan, M. *et al.* A highly conserved cryptic epitope in the receptor binding domains of
436 SARS-CoV-2 and SARS-CoV. *Science* **368**, 630-633 (2020),
437 doi:10.1126/science.abb7269.
- 438 3 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
439 conformation. *Science* **367**, 1260-1263 (2020), doi:10.1126/science.abb2507.
- 440 4 Brouwer, P. J. M. *et al.* Potent neutralizing antibodies from COVID-19 patients define
441 multiple targets of vulnerability. *Science* (2020), doi:10.1126/science.abc5902.
- 442 5 Liu, L. *et al.* Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes
443 on the SARS-CoV-2 Spike. *bioRxiv* (2020), doi:10.1101/2020.06.17.153486.
- 444 6 Wec, A. Z. *et al.* Broad neutralization of SARS-related viruses by human monoclonal
445 antibodies. *Science* (2020), doi:10.1126/science.abc7424.
- 446 7 Shi, R. *et al.* A human neutralizing antibody targets the receptor-binding site of SARS-
447 CoV-2. *Nature* (2020), doi:10.1038/s41586-020-2381-y.
- 448 8 Wu, Y. *et al.* A noncompeting pair of human neutralizing antibodies block COVID-19
449 virus binding to its receptor ACE2. *Science* **368**, 1274-1278 (2020),
450 doi:10.1126/science.abc2241.
- 451 9 Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
452 antibody. *Nature* **583**, 290-295 (2020), doi:10.1038/s41586-020-2349-y.
- 453 10 Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*
454 (2020), doi:10.1038/s41586-020-2380-z.
- 455 11 Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike
456 protein of SARS-CoV-2. *Science* (2020), doi:10.1126/science.abc6952.
- 457 12 Korber, B. *et al.* Spike mutation pipeline reveals the emergence of a more transmissible
458 form of SARS-CoV-2. *Biorxiv* **04.29.069054** (2020), doi.
- 459 13 Zhang, L. *et al.* The D614G mutation in the SARS-CoV-2 spike protein reduces S1
460 shedding and increases infectivity. *bioRxiv* (2020), doi:10.1101/2020.06.12.148726.
- 461 14 Pardi, N. *et al.* Nucleoside-modified mRNA vaccines induce potent T follicular helper
462 and germinal center B cell responses. *J Exp Med* **215**, 1571-1588 (2018),
463 doi:10.1084/jem.20171450.
- 464 15 Alameh, M. G., Weissman, D. & Pardi, N. Messenger RNA-Based Vaccines Against
465 Infectious Diseases. *Curr Top Microbiol Immunol* (2020), doi:10.1007/82_2020_202.
- 466 16 Kirchdoerfer, R. N. *et al.* Pre-fusion structure of a human coronavirus spike protein.
467 *Nature* **531**, 118-121 (2016), doi:10.1038/nature17200.
- 468 17 Kirchdoerfer, R. N. *et al.* Stabilized coronavirus spikes are resistant to conformational
469 changes induced by receptor recognition or proteolysis. *Sci Rep* **8**, 15701 (2018),
470 doi:10.1038/s41598-018-34171-7.
- 471 18 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N*
472 *Engl J Med* (2020), doi:10.1056/NEJMoa2022483.
- 473 19 Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A.,
474 Pascal K., Quandt J., Maurus D., Brachtendorf S., Lörks V., Sikorski J., Hilker R.,
475 Becker D., Eller A-K., Grütznér J., Boesler C., Rosenbaum C., Kühnle M-C.,
476 Luxemburger U., Kemmer-Brück A., Langer D., Bexon M., Bolte S., Karikó K.,

- 477 Palanche T., Fischer B., Schultz A., Shi P-Y., Fontes-Garfias C., Perez J-L., Swanson
478 K-A., Loschko J., Scully I-L., Cutler M., Kalina W., Kyratsous C.A., Cooper D.,
479 Dormitzer P.R., Jansen K.U., Türeci, O. Concurrent human antibody and T_H1 type T cell
480 responses elicited by a COVID-19 RNA vaccine. *medRxiv* (2020), doi:
481 10.1101/2020.07.17.20140533.
- 482 20 Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
483 Glycoprotein. *Cell* **181**, 281-292 e286 (2020), doi:10.1016/j.cell.2020.02.058.
- 484 21 Yurkovetskiy, L. *et al.* Structural and Functional Analysis of the D614G
485 SARS-CoV-2 Spike Protein Variant. *bioRxiv* **July 16, 2020** (2020), doi.
- 486 22 Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in
487 vaccinology. *Nat Rev Drug Discov* **17**, 261-279 (2018), doi:10.1038/nrd.2017.243.
- 488 23 Freyn, A. W. *et al.* A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus
489 Vaccine Provides Broad Protection in Mice. *Mol Ther* **28**, 1569-1584 (2020),
490 doi:10.1016/j.ymthe.2020.04.018.
- 491 24 Baiersdorfer, M. *et al.* A Facile Method for the Removal of dsRNA Contaminant from In
492 Vitro-Transcribed mRNA. *Mol Ther Nucleic Acids* **15**, 26-35 (2019),
493 doi:10.1016/j.omtn.2019.02.018.
- 494 25 Pardi, N. *et al.* Expression kinetics of nucleoside-modified mRNA delivered in lipid
495 nanoparticles to mice by various routes. *J Control Release* **217**, 345-351 (2015),
496 doi:10.1016/j.jconrel.2015.08.007.
- 497 26 Lin, P. J. *et al.* Influence of cationic lipid composition on uptake and intracellular
498 processing of lipid nanoparticle formulations of siRNA. *Nanomedicine* **9**, 233-246
499 (2013), doi:10.1016/j.nano.2012.05.019.
- 500 27 Naldini, L. *et al.* In vivo gene delivery and stable transduction of nondividing cells by a
501 lentiviral vector. *Science* **272**, 263-267 (1996), doi:10.1126/science.272.5259.263.
- 502 28 Scheres, S. H. Processing of Structurally Heterogeneous Cryo-EM Data in RELION.
503 *Methods Enzymol* **579**, 125-157 (2016), doi:10.1016/bs.mie.2016.04.012.
- 504 29 R. C Team. *A language and environment for statistical computing.* . (2019).
505